糖皮质激素与β2-受体激动剂小剂量吸入治疗哮喘临床疗效观察

摘要

Objective:To compare the clinical effect of small doses of glucocorticoid and β2-agonists inhaled in treatment of asthma.Method:86 cases of asthma from May 2012 to Mar.2014 were randomly di-vided into 2 groups, with 43 cases in each group.Observation group was treated with glucocorticoid andβ2-agonists ( budesonide and salmeterol) ,while the control group was treated with glucocorticoid ( budesonide) , the clinical curative effect of two methods were retrospectively analyzed. Re sult:After 2 weeks and 4 weeks treatment, the FEV1 of both group had growth trend, but the growth degree of observation group was obvious-ly higher than that of control group, the difference was statistically significant ( P <0.05) .Also the PEF var-iation rate of observation group was statistically significant than that of control group ( P <0.05) .Compared two groups of asthma control test score table, the patients in observation group with 0 ~1 number was signif-icantly higher than the control group, It showed that the recovery of observation group was better than control group.Patients with pharyngeal infection, cough, incidence of adverse reaction was lower than that of control group ( P <0.05) .Conclusion: Glucocorticoids and β2-agonists had important clinical value in the treat-ment of asthma that could obviously relieve asthma symptoms, promote patients recovery and reduce the inci-dence of adverse reactions.%目的：评估糖皮质激素与β2－受体激动剂小剂量吸入治疗哮喘的临床疗效。方法：将我院自2012年5月至2014年3月收治的86例哮喘患者随机分为观察组与对照组，每组43例。观察组采用糖皮质激素与β2－受体激动剂（布地奈德与沙美特罗）小剂量吸入治疗；对照组则采用糖皮质激素（布地奈德）治疗，比较两种方法的疗效。结果：两组患者分别经治疗2周与4周后，FEV1均有增长趋势，但观察组增长程度明显高于对照组，两组相比，差异有统计学意义（ P＜0．05）。且治疗后观察组患者PEF变异率较对照组相比，差异有统计学意义（ P＜0．05）。对比两组患者哮喘控制测试表得分情况，观察组患者0～1分人数明显高于对照组，表明观察者患者哮喘恢复情况明显优于对照组，且观察者治疗过程中发生咽部感染，咳嗽，皮疹等不良反应发生率较对照组明显降低（ P＜0．05）。结论：糖皮质激素与β2－受体激动剂治疗哮喘较单一糖皮质激素相比，可明显缓解哮喘症状，促进患者恢复，降低不良反应发生率，具有重要的临床价值。